

Freedom of Information Act 2000 – Request Reference FoI/24/224
Asthma Treatment

The below information reflects the period 1 December 2023 to 31 March 2024.

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab – 74
- Dupilumab – 114
- Omalizumab – 49
- Reslizumab – 0
- Mepolizumab – 43
- Tezepelumab – 62

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6–11 – 8
- Age 12–17 – 22
- Age 18 and above – 305

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- Dupilumab – 27
- Omalizumab – 18